4/6
07:46 am
atnm
Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in AML to be Presented at 2026 AACR Annual Meeting [Yahoo! Finance]
Medium
Report
Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in AML to be Presented at 2026 AACR Annual Meeting [Yahoo! Finance]
4/6
07:30 am
atnm
Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in AML to be Presented at 2026 AACR Annual Meeting
Medium
Report
Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in AML to be Presented at 2026 AACR Annual Meeting
3/31
09:21 am
atnm
Actinium Pharmaceuticals (ATNM) had its "overweight" rating reaffirmed by Stephens. They now have a $5.00 price target on the stock.
High
Report
Actinium Pharmaceuticals (ATNM) had its "overweight" rating reaffirmed by Stephens. They now have a $5.00 price target on the stock.
2/17
08:05 am
atnm
Actinium Pharmaceuticals, Inc. to Present Two Abstracts at the 2026 AACR Annual Meeting [Yahoo! Finance]
Medium
Report
Actinium Pharmaceuticals, Inc. to Present Two Abstracts at the 2026 AACR Annual Meeting [Yahoo! Finance]
2/17
07:42 am
atnm
Actinium Pharmaceuticals, Inc. to Present Two Abstracts at the 2026 AACR Annual Meeting
Medium
Report
Actinium Pharmaceuticals, Inc. to Present Two Abstracts at the 2026 AACR Annual Meeting